Tevogen Bio to Attend the 43rd Annual J.P. Morgan Healthcare Conference

12/10/24 3:13:52 PM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $TVGN alert in real time by email

WARREN, N.J., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen" or "Tevogen Bio Holdings Inc.") (NASDAQ:TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, today announced that Founder and CEO Ryan Saadi, MD, MPH, will be attending the J.P. Morgan Healthcare Conference, January 13-16, 2025, in San Francisco, CA.

The J.P. Morgan Healthcare Conference is the largest and most informative healthcare investment symposium in the industry, bringing together key stakeholders to discuss innovations and advancements in the sector.

For inquiries about Tevogen Bio's JP Morgan events, please contact Communications at [email protected]

About Tevogen Bio

Tevogen is a clinical-stage specialty immunotherapy company harnessing one of nature's most powerful immunological weapons, CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the significant unmet needs of large patient populations. Tevogen Leadership believes that sustainability and commercial success in the current era of healthcare rely on ensuring patient accessibility through advanced science and innovative business models. Tevogen has reported positive safety data from its proof-of-concept clinical trial, and its key intellectual property assets are wholly owned by the company, not subject to any third-party licensing agreements. These assets include three granted patents, nine pending US and twelve ex-US pending patents, two of which are related to artificial intelligence.

Tevogen is driven by a team of highly experienced industry leaders and distinguished scientists with drug development and global product launch experience. Tevogen's leadership believes that accessible personalized therapeutics are the next frontier of medicine, and that disruptive business models are required to sustain medical innovation.

Contacts

Tevogen Bio Communications

T: 1 877 TEVOGEN, Ext 701

[email protected]

Get the next $TVGN alert in real time by email

Introducing Nullity AI - Build Your AI Search Engine in 30 Seconds

Tevogen Bio to Attend the 43rd Annual J.P. Morgan Healthcare Conference

Chat with this insight

Recent Analyst Ratings for
$TVGN

$TVGN
SEC Filings

SEC Form 424B3 filed by Tevogen Bio Holdings Inc.

SEC Form 10-Q filed by Tevogen Bio Holdings Inc.

SEC Form NT 10-Q filed by Tevogen Bio Holdings Inc.

$TVGN
Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Tevogen Bio Holdings Inc.

Amendment: SEC Form SC 13G/A filed by Tevogen Bio Holdings Inc.

SEC Form SC 13G filed by Tevogen Bio Holdings Inc.

$TVGN
Financials

Live finance-specific insights

Tevogen Bio Secures $6 Million Series C Preferred Stock Investment

Tevogen Bio Reports Second Quarter 2024 Financial Results, Eliminates Doubt About Company's Ability to Continue as a Going Concern, Eliminates Series B Preferred Shares

$TVGN
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Officer Flomenberg Neal sold $1,747,332 worth of shares (1,078,600 units at $1.62), decreasing direct ownership by 20% to 4,254,302 units (SEC Form 4)

Chief Financial Officer Desai Kirti bought $2,460 worth of shares (3,000 units at $0.82), increasing direct ownership by 0.03% to 9,699,186 units (SEC Form 4)

Saadi Ryan H. bought $2,000 worth of shares (2,607 units at $0.77), increasing direct ownership by 0.00% to 118,252,659 units (SEC Form 4)

$TVGN
Leadership Updates

Live Leadership Updates

Tevogen Bio Announces Appointment of Anthony Tarantino as Patient Advocate to Enhance Community Engagement and Patient Support

Ryan Saadi Congratulates Marc Benioff on Receiving the Yale Legend in Leadership Award and Commends Yale School of Management for Recognizing the Importance of Integrating Corporate Success with Social Responsibility

Tevogen Bio Set to Join Russell 3000® Index

$TVGN
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Chief Financial Officer Desai Kirti bought $2,460 worth of shares (3,000 units at $0.82), increasing direct ownership by 0.03% to 9,699,186 units (SEC Form 4)

Saadi Ryan H. bought $2,000 worth of shares (2,607 units at $0.77), increasing direct ownership by 0.00% to 118,252,659 units (SEC Form 4)

$TVGN
Press Releases

Fastest customizable press release news feed in the world

Tevogen Bio Strengthens Robust IP Portfolio With Filing of Predictive AI Patent, With the Goal to Establish a Blueprint to Unlock the Full Potential of T Cell Therapies and Accelerate AI Integration to Advance Its Bold Growth Agenda

Tevogen Bio to Host Panel "Pioneering the Economics of Health: Balancing Access and Outcomes" During the 43rd Annual J.P. Morgan Healthcare Conference